QUEST DIAGNOSTICS INCORPORATED

PATIENT INFORMATION
C A,J

DOB: 09/25/1952 Age: 65
SEX: M

ID: G 4200+14

REPORT STATUS **Final**

ORDERING PHYSICIAN
SALCIDO BARRIGA EDUARDO
CLIENT INFORMATION
54904
MERCK SHARP DOHME, S DE RL DE CV
AV SAN JERONIMO #369, PISO 8
COLONIA TIZAPAN
MEXICO D.F. 01090 MEXICO,

SPECIMEN INFORMATION
SPECIMEN: 85644402
REQUISITION: 549040004674
LAB REF NO:

COLLECTED: 08/23/2018 08:00
RECEIVED: 08/30/2018 18:45
REPORTED: 09/07/2018 02:11

COMMENTS: FASTING

Test Name	In Range	Out of Range	Reference Range	Lab
HIV-1 GENOTYPE				*QDID
HIV-1 Genotype		**DETECTED**		

HIV Subtype: B

Antiretroviral drugs	Resistance Predicted	Mutations Detected
NRTIs		
ZDV (zidovudine or Retrovir)	NO	
ABC (abacavir or Ziagen)	YES	K65R,Y115F,M184V
ddI (didanosine or Videx)	YES	K65R
3TC (lamivudine or Epivir)	YES	M184V
FTC (emtricitabine or Emtriva)	YES	M184V
d4T (stavudine or Zerit)	YES	K65R
TDF (tenofovir or Viread)	YES	K65R
NNRTIs		
ETR (etravirine or Intelence)	NO	
EFV (efavirenz or Sustiva)	YES	K101E,G190S
NVP (nevirapine or Viramune)	YES	K101E,G190S
RPV (rilpivirine or Edurant)	PRB	K101E
PIs		
FPV (fos-amprenavir or Lexiva)	NO	
IDV (indinavir or Crixivan)	NO	
NFV (nelfinavir or Viracept)	NO	
SQV (saquinavir or Invirase)	NO	
LPV (lopinavir or Kaletra)	NO	
ATV (atazanavir or Reyataz)	NO	
TPV (tipranavir or Aptivus)	NO	
DRV (darunavir or Prezista)	NO	

PRB = PROBABLE OR EMERGING RESISTANCE
OTHER MUTATIONS DETECTED:
RT GENE MUTATIONS: A98S,R211K
PR GENE MUTATIONS: L63T

The Quest Diagnostics May 2018 Interpretation Algorithm
The method used in this test is RT-PCR and sequencing
Of the HIV-1 polymerase gene.

PATIENT INFORMATION
C A,J

REPORT STATUS **Final**

QUEST DIAGNOSTICS INCORPORATED

ORDERING PHYSICIAN
SALCIDO BARRIGA EDUARDO

DOB: 09/25/1952 Age: 65
SEX: M
ID: G 4200+14

COLLECTED: 08/23/2018 08:00
REPORTED: 09/07/2018 02:11

Test Name	In Range	Out of Range	Reference Range	Lab
HIV-1 GENOTYPE (Continued)				
HIV-1 Genotype (Continued)				

The phrases "resistance predicted" and "probable Or emerging resistance" refer to the application of The interpretive rules. The FDA has not reviewed all of the interpretive rules used by the laboratory to predict drug resistance. FDA may not currently recognize some of the HIV gene mutations reported as predictive of drug resistance, but the laboratory considers these mutations to be associated with resistance to anti-viral drugs based on current clinical or scientific studies. The test has been validated pursuant to CLIA regulations and is not considered investigational or for research use only. Treatment decisions should be made in consideration of All relevant clinical and laboratory findings and the prescribing information for the drugs.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Performing Laboratory Information:

*QDIDQuest Diagnostics Infectious Disease, Inc. 33608 Ortega Highway San Juan Capistrano CA 92675-2042
Laboratory Director: H J Batterman MD